Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CombiMatrix forms biothreat agents test deal:

This article was originally published in Clinica

Executive Summary

CombiMatrix has linked up with Science Applications International to develop microarrays for identifying multiple biothreat organisms. Both companies have US Department of Defense (DoD) contracts supporting the development of complementary products. Leveraging these DoD funds can help expedite the development and testing of new identification and diagnostic assays for conventional biothreat agents and emerging and genetically engineered pathogens, said Mukilteo, Washington-based CombiMatrix. Under the collaboration, Science Applications' bioinformatics know-how will be combined with CombiMatrix' multiplexed microarray technology. CombiMatrix said that under the DoD contract, it was developing electrochemical detection as an alternative to the current use of large and expensive optical readers and dyes used in fluorescence detection.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT059933

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel